Roelof Rongen

Company: Adolore BioTherapeutics

Job title: Ceo

Seminars:

Panel Discussion: Differences in Local & Systemic Immunogenicity Considerations 3:00 pm

Examining the differential immune landscapes in local and systemic gene therapies  Discussing pre-existing immunity to the transgene product in both local and systemic approaches The future role of machine learning for predicting immunogenicity risks based on preclinical and clinical data to advance personalized medicine approachesRead more

day: Conference Day Two

Pre-Conditioning Approaches for Immunogenic Vectors 10:00 am

Adolore’s approach to chronic pain Using rdHSV-CA vectors to deliver therapeutic genes Moving away from AAV to overcome immunogenicity challenges Read more

day: Conference Day Two

Workshop D – Looking into the Future: Redosing Gene Therapies 1:00 pm

Examining the differences in redosing for local gene therapies and systemic gene therapies  Understanding the regulatory bodies’ perspective on redosing Nab-positive patients Examining the challenges of redosing at high doses  Discussing the risk-benefit ratio for patients for redosing  Uncovering immunodepleting strategies to effectively enable redosingRead more

day: Clinical Track - PM